Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma TTI-622
Verified

What's the purpose of this trial?

The goal of this clinical trial is to find the best dose and learn more about the safety and effectiveness of TTI-622 in patients with advanced hematologic malignancies, including Lymphoma, Leukemia, and Multiple Myeloma.

This trial is currently open and accepting patients.


What will happen during the trial?

This trial is being conducted in two phases, 1a and 1b. During Phase 1a, researchers gave participants different doses of TTI-622 to determine which dose is best tolerated. During Phase 1b, researchers will give the best doses of TTI-622 from Phase 1a, alone or in combination with other medicines, to a larger group of participants to further evaluate its safety and effectiveness. 

This trial is open-label, which means that both participants and researchers will know which group they are placed in, and what treatments and doses they are receiving. Participants in this study may continue to receive study treatment unless they develop bad side effects, or their cancer gets worse. 

Phase 1b of this trial is further separated into smaller groups, called cohorts. The cohort of this trial you may join depends on your diagnosis and other factors. 

Reimbursement for study-related travel expenses may be available.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

• have measurable disease as defined by the trial criteria. The measurable disease criteria depends on your diagnosis, and which specific cohort you may qualify for. 
• do not have central nervous system involvement of your cancer.
• have not received a stem cell transplant in the last 90 days. 
• have not previously received treatment with an anti-CD47 and anti-SIRPa therapy.
• are not refractory to or intolerant to anti-CD38 therapy, and have not received anti-CD38 therapy in the previous 60 days. 


Additional Trial Information

Phase 1

Enrollment: 476 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

USC Norris Comprehensive Cancer Center University of Southern California

Los Angeles, CA

Open and Accepting

Florida

Tampa General Hospital Cancer Institute

Tampa, FL

Open and Accepting

Kentucky

Norton Cancer Institute (St. Matthews) St. Matthews Campus

Louisville, KY

Open and Accepting

New York

Memorial Sloan Kettering Cancer Center

New York, NY

Open and Accepting

Tennessee

University of Tennessee Medical Center Cancer Institute

Knoxville, TN

Open and Accepting

Texas

MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting

Oncology Consultants PA

Houston, TX

Open and Accepting

Washington

Swedish - Cherry Hill Campus Cherry Hill Campus

Seattle, WA

Open and Accepting

Washington, D.C.

Georgetown Lombardi Comprehensive Cancer Center Georgetown University

Washington, DC

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors